ENTRY       D11847                      Drug
NAME        Concizumab (USAN);
            Concizumab (genetical recombination) (JAN);
            Alhemo (TN)
FORMULA     C6462H10004N1712O2046S46
EXACT_MASS  145795.8549
MOL_WEIGHT  145885.808
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVKPGGSLRL SCAASGFTFS NYAMSWVRQT PEKRLEWVAT ISRSGSYSYF
            PDSVQGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARLG GYDEGDAMDS WGQGTTVTVS
            SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
            SGLYSLSSVV TVPSSSLGTK TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST
            YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE
            GNVFSCSVMH EALHNHYTQK SLSLSLGK
            (Light chain)
            DIVMTQTPLS LSVTPGQPAS ISCKSSQSLL ESDGKTYLNW YLQKPGQSPQ LLIYLVSILD
            SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQATHFP QTFGGGTKVE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (Disulfide bridge: H22-H96, H135-L219, H148-H204, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'135-L'219, H'148-H'204, H'262-H'322, H'368-H'426, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  TYPE      Peptide
REMARK      Therapeutic category: 6349
            Product: D11847<JP>
EFFICACY    Bleeding suppressant, Anti-tissue factor pathway inhibitor antibody
  TYPE      Monoclonal antibody
COMMENT     Prevention of bleeding episodes in hemophilia A and B
TARGET      TFPI [HSA:7035] [KO:K03909]
  PATHWAY   hsa04610(7035)  Complement and coagulation cascades
BRITE       Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               634  Human blood preparations
                6349  Others
                 D11847  Concizumab (USAN); Concizumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Complement and coagulation
                TFPI
                 D11847  Concizumab (USAN) &lt;JP&gt;
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11847
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11847
DBLINKS     CAS: 1312299-39-0
///
